GeNeuro awarded European patent rights for GNK-301
GeNeuro, an NRx company (Nasdaq: NRXP), received European patent rights for GNK-301, a drug candidate intended to treat amyotrophic lateral sclerosis (ALS).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.